Host Institution: SAFAN
» Info
Hypothesis: CaSR ligands could become therapeutic agents for treating calciotropic disorders such as hyperparathyroidism and non-calciotropic disorders such as cardiovascular disease, diabetes and cancer.
Objectives: Identifying and evaluating the ligand specificity of CaSR receptor modulators. ESRSAFAN will 1) Profile small molecule libraries in silico in close collaboration with the Novartis group. 2) Build a homology model for the CaSR receptor. 3) Evaluate by molecular docking the binding modes of the compounds that result from in silico profiling. 4) Analyse by molecular dynamic simulation techniques the dynamic behaviours of the receptor and of the complexes resulting from molecular docking experiments.